KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs.
Kalvista Pharmaceuticals stock last closed at $20.13, up 9.64% from the previous day, and has increased 74.44% in one year. It has overperformed other stocks in the Biotechnology industry by 1.03 percentage points. Kalvista Pharmaceuticals stock is currently +117.98% from its 52-week low of $9.24, and -2.21% from its 52-week high of $20.59.
As of Mar 31, 2026, there are 51.22M shares of KALV outstanding. The market capitalization of KALV is $1.03B. In the past 24 hours, 1.96M KALV shares were traded.
How to Buy Kalvista Pharmaceuticals Stock
Wondering how to invest in Kalvista Pharmaceuticals stock? Here's how.
Decide where to buy Kalvista Pharmaceuticals stock: You need to pick a stock brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you decide where to buy Kalvista Pharmaceuticals stock.
Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
Deposit funds into your brokerage account: Choose your method of payment and add your information.
Research Kalvista Pharmaceuticals stock: The Kalvista Pharmaceuticals ticker symbol is KALV. Is Kalvista Pharmaceuticals stock a good investment? Should you buy shares of KALV? How do KALV's underlying business fundamentals look? Do top analysts think Kalvista Pharmaceuticals is a good buy? Why has KALV's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if KALV is a good stock to buy).
Execute your KALV purchase: Decide if you will purchase KALV shares at the current market price or use a limit order to buy KALV shares at a particular price.
Track your KALV position: Create a watchlist to important notifications about your new investment in Kalvista Pharmaceuticals stock.
Step 1: Decide where to buy Kalvista Pharmaceuticals stock
You will need an online brokerage account to access the NASDAQ market and buy KALV stock.
A brokerage account is an investment account that allows you to buy and sell a variety of investments, such as stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. eToro gives you:
You can invest in stocks with zero commissions: Invest without commissions.
Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
Access to world markets: From Tech to Energy, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create your brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal info so you are able to buy KALV today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Research Kalvista Pharmaceuticals stock
Once you have chosen the best place to buy Kalvista Pharmaceuticals stock, it's absolutely critical to analyze their stock prior to investing, so you actually understand the risk as well as the opportunity.
Kalvista Pharmaceuticals Numbers
KALV Price
$20.13
1w %
22.3%
1y %
74.44%
5y %
-21.64%
P/E
N/A
P/B
-380.34x
P/S
N/A
PEG
N/A
Revenue
N/A
Earnings
N/A
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$1.03B
Next Earnings
N/A
Next Dividend
N/A
KALV Due Diligence Score
WallStreetZen was created to help part-time investors perform better fundamental analysis quickly.
Over the past 12 months, executives and large shareholders at KALV have sold more shares than they have bought.
Venrock Healthcare Capital Partners III LP, 10% Owner of KALV, was the latest KALV insider to sell. They sold $379,815.36 worth of KALV stock on Mar 26, 2026.
No, Kalvista Pharmaceuticals doesn't provide an income stream by paying out dividends.
Get analysis from other investors
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other traders have to say.
Step 5: Execute your KALV purchase
There are two main types of orders:
Market order: A market order is an order to buy or sell a security at the best available price. Market orders are usually fine for most investors.
Limit order: A limit order is an order to buy or sell a security at a specific price (or better). If you want to ensure you're buying or selling at a particular price, place a limit order.
Press the Open button and eToro will place the order.
If you want additional help investing in stocks on eToro, watch the helpful video below:
How much does it cost to buy one Kalvista Pharmaceuticals share?
As of Mar 31, 2026, it costs $20.13 to buy one share of Kalvista Pharmaceuticals stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.497 shares of KALV.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.